Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck-Reply

JAMA Oncol. 2024 Jan 1;10(1):144-145. doi: 10.1001/jamaoncol.2023.5407.

Authors

Kevin J Harrington¹, Robert Haddad²

Affiliations

¹ Royal Marsden Hospital/The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

PMID: 37991775
DOI: 10.1001/jamaoncol.2023.5407

No abstract available

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Squamous Cell* / diagnostic imaging
Carcinoma, Squamous Cell* / drug therapy
Head and Neck Neoplasms* / diagnostic imaging
Head and Neck Neoplasms* / drug therapy
Humans
Ipilimumab / adverse effects
Kidney Neoplasms* / drug therapy
Nivolumab / therapeutic use
Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

Nivolumab
Ipilimumab